FDA analysis of ineligibility for acute myeloid leukemia clinical trials by race and ethnicity

The objective of this study was to analyze the rates and reasons for trial ineligibility by race and ethnicity in trials of acute myeloid leukemia (AML) submitted to the U.S. Food and Drug Administration (FDA) between 2016-2019.

Source: Clinical Lymphoma, Myeloma and Leukemia - March 29, 2023 Category: Hematology Authors: Dianne Pulte, Laura Fernandes, Guo Wei, Ashley Woods, Kelly J. Norsworthy, Nicole Gormley, Bindu Kanapuru, Thomas E. Gwise, Richard Pazdur, Julie Schneider, Marc R. Theoret, Lola A. Fashoyin-Aje, R. Angelo de Claro Tags: Original Study Source Type: research